We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

126 hedge funds and large institutions have $676M invested in Adamas Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

64% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 33

31% more call options, than puts

Call options by funds: $8.34M | Put options by funds: $6.37M

12% more capital invested

Capital invested by funds: $602M → $676M (+$74.7M)

7% more funds holding

Funds holding: 118 → 126 (+8)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
126
Holders Change
+8
Holders Change %
+6.78%
% of All Funds
2.88%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
22
Increased
54
Reduced
33
Closed
13
Calls
$8.34M
Puts
$6.37M
Net Calls
+$1.98M
Net Calls Change
+$832K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$12.6M
2
BlackRock
BlackRock
New York
+$10M
3
BC
Broadfin Capital
New York
+$7.81M
4
SI
Sofinnova Investments
California
+$7.4M
5
Millennium Management
Millennium Management
New York
+$7.21M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$16.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.4M
3
KA
Kerrisdale Advisers
Florida
-$7.27M
4
UBS Group
UBS Group
Switzerland
-$5.29M
5
BWCA
Brenner West Capital Advisors
New York
-$4.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
126
Wellington Management Group
Massachusetts
– -$4.15M -173,770 Closed
Mirae Asset Global Investments
127
Mirae Asset Global Investments
South Korea
– -$2.04M -85,188 Closed
AI
128
Axiom Investors
Connecticut
– -$1.79M -74,910 Closed
HCM
129
Highbridge Capital Management
New York
– -$598K -25,000 Closed
Two Sigma Advisers
130
Two Sigma Advisers
New York
– -$452K -18,900 Closed
TCM
131
Tekla Capital Management
Massachusetts
– -$399K -16,699 Closed
FRM
132
Fox Run Management
Connecticut
– -$230K -9,615 Closed
SSA
133
Schonfeld Strategic Advisors
New York
– -$207K -8,627 Closed
TRCT
134
Tower Research Capital (TRC)
New York
– -$54K -2,241 Closed
Parallax Volatility Advisers
135
Parallax Volatility Advisers
California
– -$29.5K -1,066 Closed
IWM
136
IHT Wealth Management
Illinois
– -$5K -200 Closed
KF
137
Krilogy Financial
Missouri
– -$5K -200 Closed
APP
138
Avantax Planning Partners
Iowa
– -$1K -27 Closed
Northwestern Mutual Wealth Management
139
Northwestern Mutual Wealth Management
Wisconsin
– +$526 +19 New
2 3 4 5
6

ADMS Hedge Fund Activity: Q2 2018 in Review

126 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q2 2018, worth a combined $676M — up 12% from $602M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ADMS positions and 13 closed out — a net gain of 9 holders — while 54 added to existing stakes and 33 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $12.6M. The largest seller was State Street, cutting an estimated $16.9M.

  • 126 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q2 2018, up from 118 in Q1 2018.
  • Funds reported $676M of Adamas Pharmaceuticals stock for Q2 2018, up 12% quarter-over-quarter.
  • 22 funds opened new Adamas Pharmaceuticals positions in Q2 2018 and 13 closed out, a net change of +9 holders.
  • The largest Adamas Pharmaceuticals buyer in Q2 2018 was Perceptive Advisors, an estimated $12.6M added.
  • The largest Adamas Pharmaceuticals seller in Q2 2018 was State Street, an estimated $16.9M sold.

Based on aggregated 13F filings for Q2 2018.